WHEATON® Announces Acquisition of CELLineTM
News Jul 10, 2012
WHEATON has acquired the CELLine dual membrane, cell culture flasks from Wilson Wolf Manufacturing Corporation. WHEATON has also entered into a long term strategic partnership with Wilson Wolf Manufacturing Corporation for further product development in high density cell culture devices for the production of concentrated, cell secreted products. CELLine Flasks are known by their loyal users to be easy to implement and are trusted worldwide for small scale suspension and adherent cultures. The CELLine dual membrane bioreactor system is designed as a humane alternative to hybridoma culture in the peritoneal cavity of mice, also known as the ascites method.
The flasks enhance small scale bio-production for antibody and protein generation. Conventional in vivo or in vitro cell culture methods can be laborious, result in low cell density, and require significant purification. The CELLine Flasks address these three areas of limitation in a single use, repeatable technology. CELLine Flasks are ready-to-use and disposable, produce high cell density and high product concentration, while significantly reducing culture and processing time. “We are excited to bring this innovative, high growth technology to WHEATON and to our customers around the world, enabling our customers’ life’s work. These products, combined with the existing WHEATON portfolio, support the advancement of antibody and protein research, development and production,” says Stephen R. Drozdow, President of WHEATON. “We are also proud to have an ongoing partner with Wilson Wolf, for collaboration and further advancement of cell culture products,” he added.
Agilent Technologies Presents Thought Leader Award to Dr. Ram SasisekharanNews
Agilent Technologies awards Dr. Ram Sasisekharan with the Agilent Thought Leader Award in recognition of his contributions in the field of biologics characterization.READ MORE
Innate Reaction of Hematopoietic Stem Cells to Severe InfectionsNews
Researchers at the University of Zurich have shown for the first time that hematopoietic stem cells detect infectious agents themselves and begin to divide, without signals from growth factors.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018